Oramed Pharmaceuticals (ORMP) Long-Term Investments (2011 - 2026)

Oramed Pharmaceuticals has reported Long-Term Investments for 16 years, with the latest figure at $18.0 million in Q1 2026.

• For the quarter ending Q1 2026, Long-Term Investments rose 321.27% year-over-year to $18.0 million; the trailing twelve-month figure through Mar 2026 stood at $18.0 million (up 321.27% YoY), and the FY2025 full-year result was $71.6 million, up 105.77% from the prior year.
• Long-Term Investments for Q1 2026 stood at $18.0 million, down from $71.6 million in the prior quarter.
• The five-year high for Long-Term Investments was $110.2 million in Q4 2023, with the low at $7000.0 in Q1 2023.
• Historically, Long-Term Investments has averaged $21.2 million across 5 years, with a median of $4.3 million in 2025.
• Annual changes were most pronounced in 2023 — Long-Term Investments plunged 99.64% — and 2024, when it jumped 279100.0%.
• Oramed Pharmaceuticals' Long-Term Investments stood at $2.7 million in 2022, then soared by 3981.04% to $110.2 million in 2023, then plunged by 68.41% to $34.8 million in 2024, then jumped by 105.77% to $71.6 million in 2025, then slumped by 74.91% to $18.0 million in 2026.
• The last three Long-Term Investments figures came in at $18.0 million (Q1 2026), $71.6 million (Q4 2025), and $28.5 million (Q3 2025), per Business Quant data.